What’s Inside IPC’s New Consensus Statement on GPP? TDD Talks to IPC’s Chief Medical Officer Dr. Peter van de Kerkhof June 6, 2024
Zai Lab Initiates Global Phase 2 Clinical Trial of Topical 1L-17 Blocker in Chronic Plaque Psoriasis May 22, 2024
Recludix Pharma’s REX-7117 Shows Promise in Preclinical Studies of Th17-mediated Skin Inflammation May 17, 2024
Four-Year Data: Sotyktu Demonstrates Durable Response Rates, Consistent Safety in Moderate-to-Severe Plaque PsO May 17, 2024
LEO’s Enstilar Performs Well in Phase 3 Study of Adults With Stable Plaque Psoriasis in China May 7, 2024
Biosimilar News: FDA Approves High-concentration, Citrate-free Formulation of Cyltezo, a Biosimilar to Humira May 1, 2024
Biosimilar News: Two Approvals in Europe, Celltrion USA Signs Agreement with Express Scripts April 29, 2024
